<table id="ID63" width="101%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col span="1" width="20%"></col>
<col span="1" width="21%"></col>
<col span="1" width="7%"></col>
<col span="1" width="9%"></col>
<col span="1" width="7%"></col>
<col span="1" width="14%"></col>
<col span="1" width="14%"></col>
<col span="1" width="9%"></col>
<tbody>
<tr>
<td>
<br/>
</td>
<td>Losartan Potassium Tablets<br/>
</td>
<td>
<br/>
</td>
<td>Atenolol<br/>
</td>
<td>
<br/>
</td>
<td>Risk Reduction<sup>†</sup>
<br/>
</td>
<td>95 % CI<br/>
</td>
<td>p-Value<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>N (%)<br/>
</td>
<td>Rate<sup>*</sup>
<br/>
</td>
<td>N (%)<br/>
</td>
<td>Rate<sup>*</sup>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Primary Composite Endpoint<br/>
</td>
<td>508 (11)<br/>
</td>
<td>23.8<br/>
</td>
<td>588 (13)<br/>
</td>
<td>27.9<br/>
</td>
<td>13%<br/>
</td>
<td>2% to 23%<br/>
</td>
<td>0.021<br/>
</td>
</tr>
<tr>
<td>Components of  Primary Composite Endpoint (as a first event)<br/>
</td>
</tr>
<tr>
<td>Stroke (nonfatal<sup>‡</sup>)<br/>
</td>
<td>209 (5)<br/>
</td>
<td>
<br/>
</td>
<td>286 (6)<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Myocardial infarction<br/>(nonfatal<sup>‡</sup>)<br/>
</td>
<td>174 (4)<br/>
</td>
<td>
<br/>
</td>
<td>168 (4)<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Cardiovascular mortality<br/>
</td>
<td>125 (3)<br/>
</td>
<td>
<br/>
</td>
<td>134 (3)<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Secondary Endpoints (any time in study)<br/>
</td>
</tr>
<tr>
<td>Stroke (fatal/nonfatal)<br/>
</td>
<td>232 (5)<br/>
</td>
<td>10.8<br/>
</td>
<td>309 (7)<br/>
</td>
<td>14.5<br/>
</td>
<td>25%<br/>
</td>
<td>11% to 37%<br/>
</td>
<td>0.001<br/>
</td>
</tr>
<tr>
<td>Myocardial infarction<br/>(fatal/nonfatal)<br/>
</td>
<td>198 (4)<br/>
</td>
<td>9.2<br/>
</td>
<td>188 (4)<br/>
</td>
<td>8.7<br/>
</td>
<td>-7%<br/>
</td>
<td>-13% to 12%<br/>
</td>
<td>0.491<br/>
</td>
</tr>
<tr>
<td>Cardiovascular mortality<br/>
</td>
<td>204 (4)<br/>
</td>
<td>9.2<br/>
</td>
<td>234 (5)<br/>
</td>
<td>10.6<br/>
</td>
<td>11%<br/>
</td>
<td>-7% to 27%<br/>
</td>
<td>0.206<br/>
</td>
</tr>
<tr>
<td>Due to CHD<br/>
</td>
<td>125 (3)<br/>
</td>
<td>5.6<br/>
</td>
<td>124(3)<br/>
</td>
<td>5.6<br/>
</td>
<td>-3%<br/>
</td>
<td>-32% to 20%<br/>
</td>
<td>0.839<br/>
</td>
</tr>
<tr>
<td>Due to Stroke<br/>
</td>
<td>40 (1)<br/>
</td>
<td>1.8<br/>
</td>
<td>62 (1)<br/>
</td>
<td>2.8<br/>
</td>
<td>35%<br/>
</td>
<td>4% to 67%<br/>
</td>
<td>0.032<br/>
</td>
</tr>
<tr>
<td>Other <sup>§</sup>
<br/>
</td>
<td>39 (1)<br/>
</td>
<td>1.8<br/>
</td>
<td>48 (1)<br/>
</td>
<td>2.2<br/>
</td>
<td>16%<br/>
</td>
<td>-28% to 45%<br/>
</td>
<td>0.411<br/>
</td>
</tr>
<tr>
<td>
<paragraph></paragraph>
<paragraph>
<sup>*</sup> Rate per 1000 patient-years of follow-up<br/>
</paragraph>
<paragraph>
<sup>†</sup>Adjusted for baseline Framingham risk score and level of electrocardiogram left ventricular hypertrophy<br/>
</paragraph>
<paragraph>
<sup>‡</sup> First report of an event, in some cases the patient died subsequently to the event reported<br/>
</paragraph>
<paragraph>
<sup>§</sup> Death due to heart failure, non-coronary vascular disease, pulmonary embolism, or a cardiovascular cause other than stroke or coronary heart disease<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>